PeproTech重组人M-CSF(无动物成分) ,货号:AF-300-25
PeproTech重组人M-CSF(无动物成分) ,货号:AF-300-25
PeproTech重组人M-CSF(无动物成分) ,货号:AF-300-25
产地: 美国
品牌 :PeproTech
货号: AF-300-25-500
规格:10µg/1mg
供应商:深圳9游总区生物科技有限公司
英文名: Recombinant Human M-CSF
CAS号: 无
数量: 大量
保质期: 1年以上
保存条件: -20℃
Synonyms :
|
Macrophage Colony Stimulating Factor, CSF-1, MGI-IM
|
Description :
|
M-CSF is a potent hematopoietic factor produced by a variety of cells including lymphocytes, monocytes, fibroblasts, endothelial cells, myoblasts and osteoblasts. It is a key regulator of cellular proliferation, differentiation, and survival of blood monocytes, tissue macrophages and their progenitor cells. M-CSF has been shown to play important roles in modulating dermal thickness, and male and female fertility. M-CSF is clinically used in the treatment of infection, malignancies and atherosclerosis. It facilitates hematopoietic recovery after bone marrow transplantation. The human is reactive in murine systems, but the murine molecule exhibits no activity on human cells. Recombinant human M-CSF is a 36.8 kDa homodimeric protein containing two 159 amino acid polypeptide subunits.Manufactured using all non-animal reagents.
|
Catalog #:
|
AF-300-25
|
Source :
|
E.coli
|
Purity :
|
Greater than 98% by SDS-PAGE gel and HPLC analyses.
|
Endotoxin Level :
|
Endotoxin level is less than 0.1 ng per μg (1EU/μg).
|
Biological Activity :
|
The ED 50 was determined by the dose-dependent stimulation of the proliferation of murine M-NFS-60 cells is ≤ 1.0 ng/ml, corresponding to a specific activity of ≥ 1 x 106 units/mg.
|
AA Sequence :
|
MEEVSEYCSH MIGSGHLQSL QRLIDSQMET SCQITFEFVD QEQLKDPVCY LKKAFLLVQD IMEDTMRFRD NTPNAIAIVQ LQELSLRLKS CFTKDYEEHD KACVRTFYET PLQLLEKVKN VFNETKNLLD KDWNIFSKNC NNSFAECSSQ GHERQSEGS
|
PubMed Link :
|
|
Country of Origin :
|
USA
|
|
|
|
Size B
|
10µg
|
5
|
|
|
Size C
|
1mg
|
00
|
|
|
|
|
|
|
Special Sizes:
Many products can be ordered in custom sizes. Please to contact with your request.
|
|
Usage:
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
|